Outcomes of Patients with Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil beyond the Second Line: A Multicenter Retrospective Study from Saudi Arabia

Table 3

Cox hazard regression analysis of the independent progression-free survival (PFS) predictors.

	value	HR	95% CI
			Lower	Upper
Age (≥55 years)	0.719	1.024	0.647	1.622
Sex (male)	0.647	0.982	0.774	1.237
Advanced disease stage (III–IV)	0.037	2.614	1.102	7.524
Prior adjuvant therapy	0.037	0.892	0.481	0.994
Lymph node metastasis	0.018	3.664	1.187	8.650
Bone metastasis	0.036	2.790	1.073	8.221
Number of metastatic sites (>2)	0.020	1.723	1.089	2.727
Duration since diagnosis (>30 months)	0.442	1.187	0.767	1.837
Neutropenia after first cycle of FTD/TPI	0.041	0.738	0.425	0.924
Baseline absolute eosinophil count	0.022	2.089	1.027	4.910
Number of FTD/TPI cycles	0.006	0.899	0.833	0.969

HR: hazard ratio; CI: confidence interval; FTD/TPI: trifluridine/tipiracil.